Recardio

Recardio is a clinical life sciences company focused on regenerative therapies for cardiovascular diseases. The company's lead candidate drug, Dutogliptin, is a DPP-4 inhibitor that has demonstrated significant effects in activating SDF-1 (a protein crucial for cardiac regeneration). Recardio has initiated a Phase 1/2 clinical program to comprehensively develop this therapeutic platform as a regenerative medicine for various cardiovascular disease patients, including those with acute myocardial infarction and chronic heart failure, with the potential to improve cardiac function, quality of life, and survival.